Ra Pharmaceuticals, Inc. (RARX) financial statements (2022 and earlier)

Company profile

Business Address 87 CAMBRIDGE PARK DRIVE
CAMBRIDGE, MA 02140
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments264,992209,82270,381117,812
Cash and cash equivalents264,992209,82270,381117,812
Other undisclosed current assets9,7022,5852,4961,690
Total current assets:274,694212,40772,877119,502
Noncurrent Assets
Property, plant and equipment4,7325,1655,6065,537
Intangible assets, net (including goodwill)100314380445
Goodwill 183183183
Intangible assets, net (excluding goodwill)100131197262
Restricted cash and investments1,3341,3341,3341,334
Other undisclosed noncurrent assets3,292   
Total noncurrent assets:9,4586,8137,3207,316
TOTAL ASSETS:284,152219,22080,197126,818
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities16,9959,7228,2856,434
Accounts payable1,8173,2454,3483,252
Accrued liabilities15,1786,4773,9373,182
Deferred revenue and credits479329303
Other undisclosed current liabilities1,584   
Total current liabilities:18,57910,2018,6146,737
Noncurrent Liabilities
Liabilities, other than long-term debt 1,8802,3592,800
Deferred revenue and credits1,8802,3592,800
Other undisclosed noncurrent liabilities3,459214059
Total noncurrent liabilities:3,4591,9012,3992,859
Total liabilities:22,03812,10211,0139,596
Stockholders' equity
Stockholders' equity attributable to parent262,114207,11869,184117,222
Common stock47422323
Additional paid in capital552,912395,233192,375185,963
Accumulated deficit(290,845)(188,157)(123,214)(68,764)
Total stockholders' equity:262,114207,11869,184117,222
TOTAL LIABILITIES AND EQUITY:284,152219,22080,197126,818

Income statement (P&L) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues4,3142,5006454,928
Net investment income4,3141,464645109
Gross profit:4,3142,5006454,928
Operating expenses(109,979)(68,888)(55,029)(32,952)
Other undisclosed operating loss(1,314) (645) 
Operating loss:(106,979)(66,388)(55,029)(28,024)
Nonoperating income (expense)4,2911,426571(858)
Other nonoperating expense(23)(38)(74)(967)
Loss from continuing operations before income taxes:(102,688)(64,962)(54,458)(28,882)
Income tax benefit 191918
Net loss available to common stockholders, diluted:(102,688)(64,943)(54,439)(28,864)

Comprehensive Income ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(102,688)(64,943)(54,439)(28,864)
Comprehensive loss, net of tax, attributable to parent:(102,688)(64,943)(54,439)(28,864)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: